MKP peptide
Cardiovascular In trials Human trials
Also called Met-Lys-Pro
A three-amino-acid peptide released when the milk protein casein is digested. It inhibits ACE, an enzyme that raises blood pressure, and can be absorbed when taken by mouth. Because brain ACE activity is linked to cognitive decline, it has also been tested for memory and orientation.
Evidence at a glance
- Evidence
- Human trials — Studied in people
- Status
- Reached clinical trials
- Dosing
- No human study has set a dose
Human work used it as a food ingredient at small doses.
What studies report
- Lowered blood pressure in hypertensive rats
- Improved cognitive test scores in small Japanese trials of a casein-derived product
- Absorbed intact when taken by mouth
How it works
Inhibits ACE, including in the brain, where raised ACE activity is associated with neurodegeneration. Being only three amino acids, it survives digestion and is absorbed intact.
Where it acts
Acts in blood vessels, throughout the bodyThe library groups this compound under Cardiovascular. The diagram shows that target, not every tissue it reaches.
Illustrated

AI-generated subject illustration; not a depiction of the compound or evidence of its effects.
Why people take it
Reasons people seek it out — not a list of proven effects.
Status: Animal studies and small human trials as a food-derived ingredient.
- Route
- Oral — it survives digestion, unusually for a peptide
- Sequence
- Met-Lys-Pro
- Formula
- C16H30N4O4S
- Molecular weight
- 374.5 g/mol
- Available as
- 10 mg
Search PubMed for MKP peptide → We link a live search rather than a fixed citation list, so it stays current and nothing here is a reference we have not checked.
Educational information only. Nothing here is medical advice, a dosing protocol, or a recommendation to use any compound. Most entries describe substances not approved for human use. Talk to a licensed clinician before acting on anything you read here. How to read these entries.